Arpita Desai (@adesaioncmd) 's Twitter Profile
Arpita Desai

@adesaioncmd

Medical Director of GU Medical Oncology, Assistant Professor @UCSF with focus on #KidneyCancer. Alum of @UChicago. RTs not endorsements

ID: 1570922241193574400

calendar_today16-09-2022 23:47:11

251 Tweet

332 Takipçi

283 Takip Edilen

Renee Maria Saliby (@reneesaliby) 's Twitter Profile Photo

✨👩🏽‍⚕️First ASCO 's women in #GU24 women networking lunch So humbling and inspiring to meet some of the first women who paver the way for us OncoAlert

✨👩🏽‍⚕️First <a href="/ASCO/">ASCO</a> 's women in #GU24 women networking lunch 

So humbling and inspiring to meet some of the first women who paver the way for us

<a href="/OncoAlert/">OncoAlert</a>
Dena Battle (@rccadvocate) 's Twitter Profile Photo

Financial toxicity is more than drug cost! When dx with cancer, half of pts stop or reduce saving for retirement, 15% sold homes or property, 25% borrowed from friends/family. We need to assess financial burden in #kidneycancer! #GU24

Financial toxicity is more than drug cost! When dx with cancer, half of pts stop or reduce saving for retirement, 15% sold homes or property, 25% borrowed from friends/family. We need to assess financial burden in #kidneycancer! #GU24
Arpita Desai (@adesaioncmd) 's Twitter Profile Photo

Starting off Day 3 #GU24 with a phenomenal presentation by Toni Choueiri, MD showing OS survival with pembrolizumab in the adjuvant setting👉First trial to show an improvement of OS in the adjuvant setting 👉 Benefit across all sub groups 👉 38% reduction in the risk of death

Starting off Day 3 #GU24 with a phenomenal presentation by <a href="/DrChoueiri/">Toni Choueiri, MD</a> showing OS survival with pembrolizumab in the adjuvant setting👉First trial to show an improvement of OS in the adjuvant setting
 👉 Benefit across all sub groups
👉 38% reduction in the risk of death
Pavlos Msaouel (@pavlosmsaouel) 's Twitter Profile Photo

Yup. Per the latest ICH E9(R1) recs we need to carefully consider our estimands during both RCT design & transporting inferences for shared decision-making. Stay tuned for upcoming summary from #IKCS23 think tank 👉 database.ich.org/sites/default/… Stephanie Berg Tian Zhang, MD, MHS @kidneycancer

Kidney Cancer (@kidneycancer) 's Twitter Profile Photo

Less than a month 'til #KidneyCancerAwarenessMonth kicks off in March!!! Join us as we raise awareness, share stories of resilience, and #OrangeUp! kidneycancer.org/kidney-cancer-… Follow along, share, or comment how you plan to get involved. 🧡⤵️

Less than a month 'til #KidneyCancerAwarenessMonth kicks off in March!!! Join us as we raise awareness, share stories of resilience, and #OrangeUp!

kidneycancer.org/kidney-cancer-…

Follow along, share, or comment how you plan to get involved. 🧡⤵️
Toni Choueiri, MD (@drchoueiri) 's Twitter Profile Photo

1/ The long-awaited OS results from #KEYNOTE-564 are out NEJM! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC. nejm.org/doi/full/10.10…

1/ The long-awaited OS results from #KEYNOTE-564 are out <a href="/NEJM/">NEJM</a>! The 1st phase 3 trial to demonstrate a survival benefit for adjuvant treatment in #RCC.

nejm.org/doi/full/10.10…
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

My top themes of #ASCO24 for #kidneycancer, #prostatecancer, #bladdercancer, & #DevelopmentalIO -- scratches only the surface of the bountiful harvest of ASCO trials!! Looking forward to seeing/hearing from colleagues from around the world ASCO ESMO - Eur. Oncology OncoAlert

My top themes of #ASCO24 for #kidneycancer, #prostatecancer, #bladdercancer, &amp; #DevelopmentalIO -- scratches only the surface of the bountiful harvest of ASCO trials!! 
Looking forward to seeing/hearing from colleagues from around the world <a href="/ASCO/">ASCO</a> <a href="/myESMO/">ESMO - Eur. Oncology</a> <a href="/OncoAlert/">OncoAlert</a>
Neeraj Agarwal, MD, FASCO (@neerajaiims) 's Twitter Profile Photo

Fantastic meeting of IMG Oncologists (37% of practicing oncologists in USA) steered by Toni Choueiri, MD Ziad Bakouny, MD, MSc Nazli Dizman 👉Challenges faced by IMGs, Insights from the 2023 meeting, how to join the group👇ASCO #ASCO24 #IMGCoP meeting overview 👇OncoAlert #ASCODailyNews

Fantastic meeting of <a href="/IMG_Oncologists/">IMG Oncologists</a> (37% of practicing oncologists in USA) steered by <a href="/DrChoueiri/">Toni Choueiri, MD</a> <a href="/ZiadBakouny/">Ziad Bakouny, MD, MSc</a> <a href="/NazliDizman/">Nazli Dizman</a> 👉Challenges faced by IMGs, Insights from the 2023 meeting, how to join the group👇<a href="/ASCO/">ASCO</a> #ASCO24 #IMGCoP meeting overview 👇<a href="/OncoAlert/">OncoAlert</a> #ASCODailyNews
Tom Powles (@tompowles1) 's Twitter Profile Photo

Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses for axi/pembro while angiogenic signatures ⬆️ sunitinib.RNA clusters didn’t define winners. DNA/PD-L1 not helpful. VEGF in both arms is problematic #ASCO24

Biomarker data from KN426 (axi/pembro vs sunitinib) in 1st line RCC. Within arm analysis show T cell signature ⬆️ responses for axi/pembro while angiogenic signatures ⬆️ sunitinib.RNA clusters didn’t define winners. DNA/PD-L1 not helpful. VEGF in both arms is problematic #ASCO24
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Deep dive of gender equity at ASCO & #ASCOGI by Rachna Shroff, MD, MS, FASCO at #ASCO24. While moderators/discussants balanced thanks to efforts from ASCO, disparities exist in original research abstract presentations. Have thought about this a lot. There’s unlikely a singular solution but

Deep dive of gender equity at <a href="/ASCO/">ASCO</a> &amp; #ASCOGI by <a href="/rachnatshroff/">Rachna Shroff, MD, MS, FASCO</a> at #ASCO24. While moderators/discussants balanced thanks to efforts from <a href="/ASCO/">ASCO</a>, disparities exist in original research abstract presentations. 

Have thought about this a lot. There’s unlikely a singular solution but
Brian Rini, MD (@brian_rini) 's Twitter Profile Photo

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by Wenxin (Vincent) Xu (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with Laurence Albiges spotifyanchor-web.app.link/e/9vRDmeiGeKb

KIM-1 is a novel prognostic and predictive biomarker in the adjuvant RCC space. Great data at #ASCO24 and stellar discussion by <a href="/VincentWenxinXu/">Wenxin (Vincent) Xu</a> (Academy of Kidney Cancer Investigators member!). We discuss the KIM-1 data with <a href="/AlbigesL/">Laurence Albiges</a>

spotifyanchor-web.app.link/e/9vRDmeiGeKb
Sumanta K. Pal, MD, FASCO (@montypal) 's Twitter Profile Photo

Looking forward to a terrific meeting - starting tomorrow! Many thanks to the group below for helping bring forward lots of groundbreaking research.

KidneyCAN (@kidneycan) 's Twitter Profile Photo

#KCRS24 is officially kicking off! 🏁 Participants are registering, and our speakers are gearing up to share groundbreaking research and insights. Stay tuned for an exciting two days of innovation and collaboration in kidney cancer research! #KidneyCancer #AcceleratingCures

#KCRS24 is officially kicking off! 🏁 Participants are registering, and our speakers are gearing up to share groundbreaking research and insights. Stay tuned for an exciting two days of innovation and collaboration in kidney cancer research! #KidneyCancer #AcceleratingCures
Tian Zhang, MD, MHS (@tiansterzhang) 's Twitter Profile Photo

Michael Serzan, MD discusses the #ARCITECT trial in progress — botensilimab and balstilimab combination vs ipi-nivo in frontline #kidneycancer — open UTSW Simmons Cancer Center! Just gave a consent yesterday.

<a href="/MikeSerzanMD/">Michael Serzan, MD</a> discusses the #ARCITECT trial in progress — botensilimab and balstilimab combination vs ipi-nivo in frontline #kidneycancer — open <a href="/utswcancer/">UTSW Simmons Cancer Center</a>! Just gave a consent yesterday.